Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMedGoogle Scholar
• Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, Gibbs J, Kuvshinoff B, Wilding G, Warren G et al. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointestinal Oncol 2012; 3:326-34; PMID:23205309; http://dx.doi.org/10.3978/j.issn.2078-6891.2012.029
   PubMedGoogle Scholar
• Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2012; 118:2674-81; PMID:21935914; http://dx.doi.org/10.1002/cncr.26553
   PubMed Web of Science ®Google Scholar
• Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Büchler MW, Werner J. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Annals of Surg 2011; 254:311-9; PMID:21606835; http://dx.doi.org/10.1097/SLA.0b013e31821fd334
   PubMed Web of Science ®Google Scholar
• Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncology 2013; 10:323-33; PMID:23629472; http://dx.doi.org/10.1038/nrclinonc.2013.66
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 2012; 148:21-3; PMID:22265397; http://dx.doi.org/10.1016/j.cell.2011.12.021
   PubMed Web of Science ®Google Scholar
• Fox BA, Bzik DJ. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature 2002; 415:926-9; PMID:11859373; http://dx.doi.org/10.1038/415926a
   PubMed Web of Science ®Google Scholar
• Fox BA, Bzik DJ. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infect Immun 2010; 78:3744-52; PMID:20605980; http://dx.doi.org/10.1128/IAI.00287-10
   PubMed Web of Science ®Google Scholar
• Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol 2013; 190:469-78; PMID:23225891; http://dx.doi.org/10.4049/jimmunol.1201209
   PubMed Web of Science ®Google Scholar
• Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res 2013; 73:3842-51; PMID:23704211; http://dx.doi.org/10.1158/0008-5472.CAN-12-1974
   PubMed Web of Science ®Google Scholar
• Sanders KL, Fox BA, Bzik DJ. Attenuated toxoplasma gondii stimulates immunity to pancreatic cancer by manipulation of myeloid cell populations. Cancer Immunol Res 2015; 3:891-901; PMID:25804437; http://dx.doi.org/10.1158/2326-6066.CIR-14-0235
   PubMed Web of Science ®Google Scholar
• Fox BA, Sanders KL, Bzik DJ. Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression. Oncoimmunology 2013; 2:e26296; PMID:24353916; http://dx.doi.org/10.4161/onci.26296
   PubMedGoogle Scholar
• Fox BA, Sanders KL, Chen S, Bzik DJ. Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines. Trends Parasitol 2013; 29:431-7; PMID:23928100; http://dx.doi.org/10.1016/j.pt.2013.07.001
   PubMed Web of Science ®Google Scholar
• Ahn SS, Irie RF, Weisenburger TH, Jones PC, Juillard G, Roe DJ, Morton DL. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response. Surgery 1982; 92:362-7; PMID:7101129
   PubMed Web of Science ®Google Scholar
• GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher T, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA et al. Humoral immune response against non-targeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res 2015; 21:3619-30; PMID:25649018; http://dx.doi.org/10.1158/1078-0432.CCR-14-2334
   Web of Science ®Google Scholar
• Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16:2913-20; PMID:9738558
   PubMed Web of Science ®Google Scholar
• Qin L, Smith BD, Tsai HL, Yaghi NK, Neela PH, Moake M, Fu J, Kasamon YL, Prince GT, Goswami M et al. Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. Blood Cancer J 2013; 3:e145; PMID:24013666; http://dx.doi.org/10.1038/bcj.2013.44
   PubMed Web of Science ®Google Scholar
• Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013; 108:914-23; PMID:23385730; http://dx.doi.org/10.1038/bjc.2013.32
   PubMed Web of Science ®Google Scholar
• Jordan KA, Wilson EH, Tait ED, Fox BA, Roos DS, Bzik DJ, Dzierszinski F, Hunter CA. Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii. Infect Immun 2009; 77:3894-901; PMID:19528214; http://dx.doi.org/10.1128/IAI.00024-09
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Tsai LM, Yu D. Follicular helper T-cell memory: establishing new frontiers during antibody response. Immunol Cell Biol 2014; 92:57-63; PMID:24189164; http://dx.doi.org/10.1038/icb.2013.68
   PubMed Web of Science ®Google Scholar
• Gigley JP, Fox BA, Bzik DJ. Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication. J Immunol 2009; 182:1069-78; PMID:19124750; http://dx.doi.org/10.4049/jimmunol.182.2.1069
   PubMed Web of Science ®Google Scholar
• Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Jr, Schabel FM Jr. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984; 44:717-26; PMID:6692374
   PubMed Web of Science ®Google Scholar